Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2019
February 13, 2020 at 03:38 pm EST
Share
Sangui Biotech International, Inc. announced earnings results for the second quarter ended December 31, 2019. For the second quarter, the company announced operating loss was USD 36,533 compared to USD 60,137 a year ago. Net loss was USD 53,983 compared to USD 56,356 a year ago. For the half year, operating loss was USD 92,431 compared to USD 153,635 a year ago. Net loss was USD 96,732 compared to USD 146,319 a year ago.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
